Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos
- 30 June 2012
- journal article
- Published by Elsevier BV in Bone
- Vol. 50 (6), 1207-1213
- https://doi.org/10.1016/j.bone.2012.03.022
Abstract
No abstract availableKeywords
Funding Information
- World Class Institute (WCI) Program (WCI 2009-002)
- Ministry of Education, Science and Technology (MEST)
- Technology Development Program for Agriculture and Forestry
- Ministry for Agriculture, Forestry and Fisheries
- KRIBB Research Initiative Program
This publication has 32 references indexed in Scilit:
- Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53Cancer Letters, 2011
- Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL‐induced activation of NF‐κB and ERKJournal of Cellular Biochemistry, 2011
- Epigallocatechin-3-gallate Inhibits Osteoclastogenesis by Down-Regulating c-Fos Expression and Suppressing the Nuclear Factor-κB SignalMolecular Pharmacology, 2009
- Potential Role of Ginseng in the Treatment of Colorectal CancerThe American Journal of Chinese Medicine, 2008
- Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyteBiochemical and Biophysical Research Communications, 2007
- Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systemsNature Reviews Immunology, 2007
- Osteoclast differentiation and activationNature, 2003
- Microphthalmia Transcription Factor Is a Target of the p38 MAPK Pathway in Response to Receptor Activator of NF-κB Ligand SignalingOnline Journal of Public Health Informatics, 2002
- Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)Online Journal of Public Health Informatics, 2000
- Requirement for NF-κB in osteoclast and B-cell developmentGenes & Development, 1997